官方服务：
资源简介：
RNA-seq in L3.6pl upon treatment with JQ1
应用场景：
创建时间：
2025-07-08
相关数据集
DUB3 promotes BET inhibitor resistance and cancer progression through deubiquitinating BRD4. Jin et al
The bromodomain and extra-terminal domain (BET) protein BRD4 is emerging as a promising anticancer therapeutic target. However, resistance to BET inhibitors often occurs, and it has been linked to abe
Mendeley Data2024-06-25 更新130
DUB3 promotes BET inhibitor resistance and cancer progression through deubiquitinating BRD4. Jin et al
The bromodomain and extra-terminal domain (BET) protein BRD4 is emerging as a promising anticancer therapeutic target. However, resistance to BET inhibitors often occurs, and it has been linked to abe
NIAID Data Ecosystem90
LNCaP treated with iBET
BRD4 belongs to the bromodomain and extraterminal (BET) family of epigenetic reader proteins that bind acetylated histones and regulate gene expression. Pharmacological inhibition of BRD4 by BET inhib
NIAID Data Ecosystem20
High Resolution Mapping of RNA Polymerases Identifies Mechanisms of Sensitivity and Resistance to BET Inhibitors in t(8;21) AML
Bromodomain and extra-terminal domain (BET) family inhibitors offer a new approach to treating hematological malignancies. We used precision nuclear run-on transcription sequencing (PRO-seq) to create
NIAID Data Ecosystem100
RNA-seq analysis of SCC1 cells after JQ1, I-BET and/or INF-r treatment. RNA-seq analysis of SCC1 cells after JQ1, I-BET and/or INF-r treatment
In order to examine how BET inhibition affects the gene transcriptome in HNSCC cells, we performed RNA-sequencing in SCC1 cells treated with JQ1, I-BET, and/or INF-r. Overall design: Examination of RN
NIAID Data Ecosystem20
